Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 19Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Hodgkin Disease 13Multiple Myeloma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 9Glioblastoma 9Lymphoma, B-Cell, Marginal Zone 8Burkitt Lymphoma 8Brain Neoplasms 8Sezary Syndrome 7Neoplasms 7Lymphoma, T-Cell, Cutaneous 7Leukemia 7Congenital Abnormalities 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Neuroblastoma 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large-Cell, Anaplastic 6Breast Neoplasms, Male 6Sarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × Vorinostat × Clear all
NCT00132067 2019-07-23

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡